Navigation Links
Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
Date:6/1/2009

ALISO VIEJO, Calif., June 1 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals International (NYSE: VRX) today reported final results for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in development for the treatment of chronic hepatitis C in conjunction with a pegylated interferon. The study in treatment naive genotype 1 infected subjects was of standard design, consisting of 48 weeks of treatment with a 24-week follow-up period. It explored three weight-based doses of taribavirin: 20 mg/kg, 25 mg/kg and 30 mg/kg vs. ribavirin 800-1400 mg/day. Throughout the 72-week trial, all doses of taribavirin demonstrated comparable efficacy (sustained virologic response (SVR)) to ribavirin with consistently lower levels of anemia. In addition, relapse rates in the 25 mg/kg and 30 mg/kg arms were comparable with the ribavirin arm; supporting the premise that higher dose weight-based taribavirin may be as effective as weight based ribavirin. Valeant plans to present the full final data at the American Association for the Study of Liver Disease (AASLD) later this year.

"The final results of this Phase II study are promising and imply that comparable efficacy with taribavirin can be achieved when compared to ribavirin," stated Fred Poordad, M.D., Chief of Hepatology at the Center for Liver Disease and Transplantation, Cedars-Sinai Medical Center, Los Angeles, CA. "As is known for ribavirin, low doses are associated with a high relapse rate and, except for the lowest dose with taribavirin, relapse rates are also comparable to ribavirin. The safety of this ribavirin analog is of particular relevance in the evolving era of small molecule therapies as anemia appears to be more problematic."

"We are very pleased with the results from this dose finding study which confirms th
'/>"/>

SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DFB Sells Coria Labs to Valeant Pharmaceuticals
2. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
3. Valeant Pharmaceuticals Completes Acquisition of Dow Pharmaceutical Sciences, Inc.
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 18, 2014 Scientists at NYU Langone Medical ... the efficiency of the process for turning adult cells ... compounds, including vitamin C. Using the new technique in ... obtained from adult skin cells by more than 20-fold ... is efficient and reliable, and thus should generally accelerate ...
(Date:9/19/2014)... California (PRWEB) September 19, 2014 ... and its potential to revolutionize the world has ... multinational corporations and small start-ups. The early years ... research projects largely due to the high risks ... Government budgets earmarked for this evolving technology have ...
(Date:9/19/2014)... , September 19, 2014 ... technology, development of emerging drug systems and advanced Laboratory ... Dickinson and Company (NYSE: BDX ), Thermo ... Biosciences Inc. (NASDAQ: RGDO ), Sangamo Biosciences ... (NASDAQ: HOLX) Pressure BioSciences, Inc. (OTCQB: PBIO) ...
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
Breaking Biology Technology:NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7Pfenex to Present at Upcoming Industry Conference on September 26 2
... ARAY ), a global leader in ... official journal of the Congress of Neurological,Surgeons, has ... , The supplement, titled ... different countries, focused on brain and spine,treatment using ...
... Inc. (ERT), (Nasdaq: ERES ), ... to provide integrated Cardiac Safety and Ambulatory ... to clinical trial sponsors and managers worldwide.eResearchTechnology ... (ECG), eClinical technology, ePRO, and other services ...
... Cell Technologies, Inc., a leader in adult stem cell production, announced ... Dr. Bayer will be responsible for developing pre-clinical and clinical ... trials using Stemedica products. , ... San Diego, CA ...
Cached Biology Technology:Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience 2Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience 3Neurosurgery Journal Issues Supplement Dedicated to CyberKnife Radiosurgery Experience 4ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 2ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 3ERT (eResearchTechnology, Inc.) and Integrium, LLC Form Alliance to Deliver Integrated Cardiac Safety and Ambulatory Blood Pressure Monitoring Services 4Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 2Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services 3
(Date:9/19/2014)... for the sake of fairness per se but in ... say Frans de Waal, PhD, and Sarah Brosnan, PhD, ... which is defined as a negative reaction to unequal ... , Their conclusion comes after the co-authors reviewed ... that it is the evolution of forestalling partner dissatisfaction ...
(Date:9/18/2014)... PULLMAN, Wash. - Washington State University researchers have developed ... sediment to power waste cleanup in rural areas. ... lead to an inexpensive and quick way to clean ... treatment plants while reducing pollution. , Professor Haluk ... College of Engineering and Architecture discuss the system in ...
(Date:9/18/2014)... 18, 2014 New research into the Crimean-Congo hemorrhagic ... severe hemorrhagic disease in humans similar to that caused ... CCHFV infection. This discovery has the potential to lead ... , The research, reported in a paper ... and conducted by scientists at the Texas Biomedical Research ...
Breaking Biology News(10 mins):Evolution of responses to (un)fairness 2Evolution of responses to (un)fairness 3Researchers develop unique waste cleanup for rural areas 2Research milestone in CCHF virus could help identify new treatments 2
... fuel sources are lighting a fire under research to turn ... Bill 20, signed this week by Gov. Rick Perry, compliments ... used. The new law requires more renewable energy to be ... consumer energy needs and agriculture industry trends with the legislation ...
... some day be defeated by a single treatment, according ... University of Georgia's College of Veterinary Medicine. , Their ... and Marburg and includes investigators from Vanderbilt University Medical ... The study is being funded by a grant from ...
... Berkeley, has found that damage to a cell's DNA sets ... of a marker recognized by the body's immune system. , ... advanced online issue of Nature, shed light on a long-standing ... are able to attack tumors - can differentiate cells that ...
Cached Biology News:Researchers find ways to turn manure into power 2Researchers find ways to turn manure into power 3Researcher at UGA College of Veterinary Medicine identifies new way of combating viral diseases 2New study finds how cells with damaged DNA alert the immune system 2New study finds how cells with damaged DNA alert the immune system 3
... Polymerase I Large (Klenow) Fragment, Exonuclease Minus, ... both the 5´→3´ and the 3´→5´ exonuclease ... Polymerase I (1,2). It is used for ... displacement amplification (5). Klenow Fragment, Exonuclease Minus, ...
Goat polyclonal to Duffy / FY / DARC...
... centrifuge offers both high-speed and high-volume ... of rotor options, making it ideal for ... Maximum Versatility , High-speed (up to ... or high-volume (4 x 250mL) swinging bucket ...
... fully licensed, high throughput, water bath thermal cycler ... 24 microplates. This equates to 9,216 reactions per ... robotic arm rapidly transfers a basket of plates ... times that are considerably faster than those of ...
Biology Products: